Telomir Pharmaceuticals climbs on promising breast cancer therapy data

Telomir Pharmaceuticals

09/10/2025 12:36

** Shares of drug developer Telomir Pharmaceuticals TELO.O rise 17% to $1.93 premarket

** Co said late on Wednesday its experimental drug, Telomir-1, was able to kill aggressive triple-negative breast cancer cells in lab studies by disrupting how the cells use iron and energy

** The drug worked by shutting down energy production in the cancer cells, which rely heavily on iron to grow and survive, co said

** Earlier this week, co said Telomir-1 restored the activity of two key tumor-suppressing genes in aggressive prostate cancer

** Co plans to seek U.S. regulatory clearance to begin human trials of Telomir-1 by the end of the year

** As of last close, stock was down 60% YTD

 (Reporting by Kamal Choudhury in Bengaluru)

 ((Kamal.Choudhury@thomsonreuters.com;))